NCT00905034 - Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Leukemia, Lymphocytic, Acute

Interventions

DRUG

Methotrexate

200 mg/m\^2 by vein on days 1 and 15.

DRUG

Vincristine

1.4 mg/m\^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.

DRUG

PEG-l-asparaginase

2500 International units/m\^2 by vein on days 2 and 16

DRUG

Dexamethasone

40 mg by vein or by mouth daily days 1-4 and 15-18.

DRUG

Rituximab

Rituximab 375 mg/m\^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston